Montelukast

Montelukast selectively blocks the cysteinyl leukotriene receptor CysLT1. This inhibition prevents leukotriene D4 from binding, which in turn reduces bronchoconstriction, mucus production, and inflammatory cell recruitment in the respiratory tract.

The appropriate dose of Montelukast is determined by the prescribing healthcare professional based on the patient’s age, condition, and clinical response. Typical regimens may vary, but the exact dosage and frequency should always follow the prescriber’s instructions.

Safety data for Montelukast in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or other leukotriene blockers such as zafirlukast. It is generally well‑tolerated and convenient for once‑daily dosing, but the choice depends on individual disease severity, response, and physician preference.

Montelukast tablets should be stored below 25 °C in their original packaging, protected from moisture and direct sunlight. Keep the container tightly closed and out of reach of children to maintain product stability and potency.

Montelukast is taken orally as a tablet, swallowed whole with or without food. The tablet should be consumed at the same time each day, and patients should follow the dosing schedule prescribed by their healthcare professional.

Serious adverse events include allergic reactions such as rash or angioedema, neuropsychiatric effects like depression or suicidal thoughts, elevated liver enzymes, and rare conditions such as eosinophilic granulomatosis with polyangiitis. Any of these symptoms warrant immediate medical attention.

Montelukast is contraindicated in individuals with known hypersensitivity to the drug or any of its excipients. Patients with a history of severe neuropsychiatric disorders or uncontrolled liver disease should discuss risks with their clinician before initiating therapy.